ADCs will be developed using CRT antibodies and peptides and ADCT’s ‘ warhead’ and linker chemistries.
As part of the development programme, ADCT will grant funds for preclinical ADC studies in the laboratories at Queen Mary, UCL (University of London) and King’s College London.
The deal terms and cancer targets have not been disclosed.
ADCT collaboration manager Chris Martin said,"We are very excited to see our potent PBD-based warheads combined with CRT’s leading tumour-targeting antibodies and peptides.”
CRT business management director Phil L’Huillier said there is very promising evidence that ADCs could be an important new way to treat cancer.
”This unique collaboration marries ADCT’s targeted portfolio with CRT’s access to world-class cancer research supported by £334 million each year,"Huillier added.
The drug targets the cancer cells and delivers tumour-destroying chemicals avoiding damage to healthy tissues.